CD274 and head and neck squamous cell carcinoma: Furthermore, clinical studies have shown that PD-L1-high HNSCC patients treated with a PD-L1 inhibitor combined with 5-azacytidine (5-aza) experienced a significant extension in overall survival (OS) (NCT03019003) (130).